Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Kyle A. Cottrell"'
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Abstract Tumor cells require nominal increases in protein synthesis in order to maintain high proliferation rates. As such, tumor cells must acquire enhanced ribosome production. How the numerous mutations in tumor cells ultimately achieve this aberr
Externí odkaz:
https://doaj.org/article/60e397c48e944433a97436aa66b949cd
Autor:
Manasvi Verma, Junhong Choi, Kyle A. Cottrell, Zeno Lavagnino, Erica N. Thomas, Slavica Pavlovic-Djuranovic, Pawel Szczesny, David W. Piston, Hani S. Zaher, Joseph D. Puglisi, Sergej Djuranovic
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
Several factors contribute to the efficiency of protein expression. Here the authors show that the identity of amino acids encoded by codons at position 3–5 significantly impact translation efficiency and protein expression levels.
Externí odkaz:
https://doaj.org/article/d6c7739bcd3d4753818faecc0bc65dc2
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
A large number of RNA binding proteins (RBPs) and miRNAs bind to the 3′ untranslated regions of mRNA, but methods to dissect their function and interactions are lacking. Here the authors introduce post-transcriptional regulatory element sequencing
Externí odkaz:
https://doaj.org/article/860a849ac3354dd6b652646c9de5a8c5
Publikováno v:
Cancer Res Commun
The RNA editing enzyme ADAR is an attractive therapeutic target for multiple cancers. Through its deaminase activity, ADAR edits adenosine to inosine in double-stranded RNAs. Loss of ADAR in some cancer cell lines causes activation of the type I IFN
The RNA editing enzyme ADAR, is an attractive therapeutic target for multiple cancers. Through its deaminase activity, ADAR edits adenosine to inosine in dsRNAs. Loss of ADAR in some cancer cell lines causes activation of the type I interferon pathwa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e2e7dd681a2dc91af22d51e0eb3446f
https://doi.org/10.1101/2021.05.12.443853
https://doi.org/10.1101/2021.05.12.443853
Publikováno v:
Cancer Research. 82:876-876
The RNA editing enzyme ADAR has been identified as a therapeutic target for multiple cancers. Through its A-to-I editing activity the p150 isoform of ADAR suppresses activation of dsRNA sensors involved in the innate immune response and translational
Publikováno v:
Cancer Research. 82:842-842
Adenosine deaminase acting on RNA (ADAR) is an RNA-editing enzyme that binds dsRNA and converts adenosine to inosine. ADAR promotes cell survival and proliferation in multiple types of tumors, including breast cancer. However, the mechanism of ADAR-d
Autor:
Thwisha Sabloak, Emily A. Bao, Eric Freeman, Raleigh D. Kladney, Sua Ryu, Leonard B. Maggi, Emily R. Bramel, Kyle A. Cottrell, Che-Pei Kung, Jason D. Weber
Publikováno v:
Oncogene
Triple-negative breast cancer (TNBC) is the deadliest form of breast cancer. Unlike other types of breast cancer that can be effectively treated by targeted therapies, no such targeted therapy exists for all TNBC patients. The ADAR1 enzyme carries ou
Tumor cells require nominal increases in protein synthesis in order to maintain high proliferation rates. As such, tumor cells must acquire enhanced ribosome production. How many of the mutations in tumor cells ultimately achieve this aberrant produc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8227b42e08e0ed57d1d7e9b52c033f32
Autor:
Leonard B. Maggi, Raleigh D. Kladney, Emily A. Bross, Che-Pei Kung, Kyle A. Cottrell, Emily R. Bramel, Sua Ryu, Jason D. Weber
SummaryTriple-negative breast cancer (TNBC) is the deadliest form of breast cancer. Unlike other types of breast cancer that can be effectively treated by targeted therapies, no such targeted therapy exists for all TNBC patients. The ADAR1 enzyme car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::234a8fa2dac3813abaa1df7b8dc610ea